EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line

Nishimura,Yukio; Takiguchi,Soichi; Ito,Shigeru; Itoh,Kazuyuki

doi:10.3892/ijo.2015.2871

EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line

Authors:
- Yukio Nishimura
- Soichi Takiguchi
- Shigeru Ito
- Kazuyuki Itoh
View Affiliations

Affiliations: Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812‑8582, Japan, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811‑1395, Japan, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo 101‑0062, Japan, Department of Biology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537‑8511, Japan
Published online on: February 4, 2015 https://doi.org/10.3892/ijo.2015.2871
Pages: 1721-1729

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The receptor tyrosine kinase epidermal growth factor receptor (EGFR) and its ligand epidermal growth factor (EGF) are known to play important roles in malignant tumor cells, and the EGFR signaling pathway is one of the most important targets in various tumors, including non‑small cell lung cancer (NSCLC). We reported recently that an aberration in certain steps of EGF‑stimulated phosphorylated epidermal growth factor receptor (pEGFR) endocytic trafficking from the early endosomes to the late endosomes occurs in the gefitinib‑resistant NSCLC cells, in which large amounts of sorting nexin 1 (SNX1) are colocalized with EGFR in the aggregated early endosomes where the internalized pEGFR is also accumulated of these cells. To further investigate the role of SNX1 in EGF‑stimulated pEGFR endocytosis, followed by downstream signaling leading to the activation of phosphatidylinositol 3‑kinase (PI3K)‑the serine/threonine kinase AKT pathway, we examined the effect of depletion of SNX1 knock‑down expression by siRNA and an inhibition of targeting membrane recycling using monensin. Using immunofluorescence, we observed an efficient endocytic transport of pEGFR from early endosomes to late endosomes/lysosomes after EGF‑stimulation in the cells transfected with siRNA‑SNX1, whereas the delayed endocytic delivery of pEGFR was evident in the siRNA‑control‑transfected cells. Furthermore, a large amount of endocytosed pEGFR was accumulated in the presence of monensin in the early endosomes of the SNX1 knock‑down cells. In western blot analysis, EGF stimulation of both control and cells transfected with siRNA‑SNX1 resulted in rapid phosphorylation of EGFR and enhanced AKT phosphorylation. Monensin‑dependent inhibition of AKT phosphorylation was stronger in SNX1 knock‑down cells than in controls. In contrast, however, monensin had no effect on AKT phosphorylation triggered by activation of the MET receptor tyrosine kinase. Collectively, we suggest that EGF‑stimulated recycling of EGFR to the plasma membrane induces downstream signaling leading to AKT phosphorylation. Suppression of EGFR membrane recycling by SNX1 appears to be critical for the activation of EGFR/PI3K/AKT signaling pathway in human lung cancer cells.

View Figures

View References

1	de Bono JS and Rowinsky EK: The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 8(Suppl 4): S19–S26. 2002. View Article : Google Scholar : PubMed/NCBI
2	Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 19:6550–6565. 2000. View Article : Google Scholar
3	Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem. 265:7709–7712. 1990.PubMed/NCBI
4	Yarden Y: The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar
5	Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell. 61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
6	Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 306:1506–1507. 2004. View Article : Google Scholar : PubMed/NCBI
7	Engelman JA and Cantley LC: The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 12:4372s–4376s. 2006. View Article : Google Scholar : PubMed/NCBI
8	Henne WM, Buchkovich NJ and Emr SD: The ESCRT pathway. Dev Cell. 21:77–91. 2011. View Article : Google Scholar : PubMed/NCBI
9	Arteaga CL and Johnson DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 13:491–498. 2001. View Article : Google Scholar : PubMed/NCBI
10	Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L and Richards L: Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett. 11:1911–1914. 2001. View Article : Google Scholar : PubMed/NCBI
11	Baselga J and Averbuch SD: ZD1839 (‘Iressa’) as an anticancer agent. Drugs. 60(Suppl 1): S33–S42. 2000. View Article : Google Scholar
12	Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
13	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
14	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
15	Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Jänne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
16	Nishimura Y, Bereczky B and Ono M: The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol. 127:541–553. 2007. View Article : Google Scholar : PubMed/NCBI
17	Nishimura Y, Yoshioka K, Bereczky B and Itoh K: Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Mol Cancer. 7:422008. View Article : Google Scholar : PubMed/NCBI
18	Nishimura Y, Yoshioka K, Takiguchi S, Bereczky B, Nakabeppu Y and Itoh K: A role for SNX1 in the regulation of EGF-dependent phosphorylated EGFR endocytosis via the early/late endocytic pathway in a gefitinib-sensitive human lung cancer cells. Curr Signal Transduct Ther. 6:383–395. 2011. View Article : Google Scholar
19	Nishimura Y, Takiguchi S, Yoshioka K, Nakabeppu Y and Itoh K: Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines. Int J Oncol. 41:1520–1530. 2012.PubMed/NCBI
20	Nishimura Y, Takiguchi S, Ito S and Itoh K: Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line. Int J Oncol. 44:412–426. 2014.
21	Kurten RC, Cadena DL and Gill GN: Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science. 272:1008–1010. 1996. View Article : Google Scholar : PubMed/NCBI
22	Worby CA and Dixon JE: Sorting out the cellular function of sorting nexins. Nat Rev Mol Cell Biol. 3:919–931. 2002. View Article : Google Scholar : PubMed/NCBI
23	Zhong Q, Lasar CS, Tronchère H, Sato T, Meerloo T, Yeo M, Songyang Z, Emr SD and Gill GN: Endosomal localization and function of sorting nexin 1. Proc Natl Acad Sci USA. 99:6767–6772. 2002. View Article : Google Scholar : PubMed/NCBI
24	Carlton J, Bujny M, Peter BJ, Oorschot VM, Rutherford A, Mellor H, Klumperman J, McMahon HT and Cullen PJ: Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high-curvature membranes and 3-phosphoinositides. Curr Biol. 14:1791–1800. 2004. View Article : Google Scholar : PubMed/NCBI
25	Gullapalli A, Garrett TA, Paing MM, Griffin CT, Yang Y and Trejo J: A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking. Mol Biol Cell. 15:2143–2155. 2004. View Article : Google Scholar : PubMed/NCBI
26	Nishimura Y, Higaki M and Kato K: Identification of a precursor form of cathepsin D in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Biochem Biophys Res Commun. 148:335–343. 1987. View Article : Google Scholar : PubMed/NCBI
27	Nishimura Y, Kawabata T and Kato K: Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys. 261:64–71. 1988. View Article : Google Scholar : PubMed/NCBI
28	Kornfeld S and Mellman I: The biogenesis of lysosomes. Ann Rev Cell Biol. 5:483–525. 1989. View Article : Google Scholar : PubMed/NCBI
29	Sandoval IV, Arredondo JJ, Alcalde J, Gonzalez-Noriega A, Vandekerckhove J, Jimenez MA and Rico M: The residues Leu(Ile)475-Ile(Leu, Val, Ala)476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMP II to lysosomes. J Biol Chem. 269:6622–6631. 1994.PubMed/NCBI
30	Jones MC, Caswell PT and Norman JC: Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol. 18:549–557. 2006. View Article : Google Scholar : PubMed/NCBI
31	Felder S, Miller K, Moehren G, Ullrich A, Schlessinger J and Hopkins CR: Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body. Cell. 61:623–634. 1990. View Article : Google Scholar : PubMed/NCBI
32	Ullrich O, Reinsch S, Urbé S, Zerial M and Parton RG: Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol. 135:913–924. 1996. View Article : Google Scholar : PubMed/NCBI
33	Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB and Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 7:261–269. 1997. View Article : Google Scholar : PubMed/NCBI
34	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
35	Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 127:125–137. 2006. View Article : Google Scholar : PubMed/NCBI